Mature T-cell and NK-cell non-Hodgkin lymphoma

This study tests adding the drug romidepsin to standard chemotherapy (CHOEP) for young adults (ages 18-65) with a rare type of lymphoma called peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective before patients undergo a stem cell transplant. …

This phase II trial is testing whether combining brentuximab vedotin, a targeted antibody-drug conjugate, with lenalidomide, a chemotherapy drug, can shrink tumors in people with T-cell lymphoma that has relapsed or not responded to earlier treatment. The study enrolls adults wit…

This early-phase trial tested a combination of four drugs (romidepsin, CC-486, dexamethasone, and lenalidomide) in 26 adults with T-cell cancers that had returned or stopped responding to prior treatments. The main goal was to find a safe dose and check for side effects. While th…

This study tested a combination of the targeted drug brentuximab vedotin (ADCETRIS) plus standard CHP chemotherapy in 82 people with newly diagnosed peripheral T-cell lymphoma (PTCL) that has low CD30 levels. The goal was to see how many patients' tumors shrank or disappeared. Re…

This phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemother…

This study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant could help keep lymphoma from coming back. It included 82 adults with relapsed or hard-to-treat Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma. The goal was to …

This study tested a combination of two drugs, nivolumab and cabiralizumab, in 4 adults with a rare and aggressive blood cancer called peripheral T-cell lymphoma that had come back or not responded to prior treatments. The goal was to see if the drug pair could shrink tumors. The …

This completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. …

This study tested a new drug called HX009 in 48 Chinese patients with lymphoma that had relapsed or not responded to prior treatments. HX009 is a dual-target antibody designed to block two proteins (CD47 and PD-1) that help cancer cells hide from the immune system. The goal was t…

This early-phase trial tested a combination of four drugs—romidepsin, gemcitabine, dexamethasone, and cisplatin—in 21 people with peripheral T-cell or diffuse large B-cell lymphoma who had already tried other treatments. The main goal was to find a safe dose of romidepsin when ad…

This study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …

This study tested a new drug called XNW5004 in 120 people with advanced tumors or lymphoma that had come back or stopped responding to standard treatments. The goal was to check the drug's safety, find the right dose, and see if it helps shrink tumors. The drug is taken as a tabl…

This phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with targeted radiation therapy could help patients whose non-Hodgkin lymphoma had returned or stopped responding to treatment. Seventeen adults with aggressive lymphoma types received bo…

This phase 2 trial tested an oral drug called AZD4205 in 57 adults with relapsed or refractory peripheral T-cell lymphoma, a rare blood cancer. The study aimed to see if the drug can shrink tumors and how safe it is. Participants took a capsule once daily in 28-day cycles.

This study tested a drug called brentuximab vedotin in 23 people with a type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, even when levels of…

This early-phase trial tested whether adding the drug romidepsin before and after a stem cell transplant could help control T-cell cancers like lymphoma and leukemia. Twenty-three patients received romidepsin along with standard chemotherapy, followed by a donor stem cell transpl…

This early-phase trial tested an experimental drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to prior treatments. The main goals were to find a safe dose and check for side effects. The study is complete, but it is …

This early-phase trial tested a new drug called PTX-100 in 25 people with advanced cancers like multiple myeloma, lymphoma, and certain solid tumors. The goal was to find safe doses and understand how the drug behaves in the body. Participants received the drug by IV for five day…

This completed study analyzed data from 249 adults with blood cancers like lymphoma and leukemia who received immunotherapy. The goal was to find markers—such as patient history or lab results—that could predict who will respond well and who might have severe side effects. By ide…